drugset / Trial / NCT00086034

Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma

NCT00086034

Phase 2 Completed 35 enrolled Pharmacyclics LLC.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to find out if motexafin gadolinium may be an effective treatment for patients with non-Hodgkin's lymphoma (NHL). Secondly, the safety and side effects of motexafin gadolinium will be evaluated.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject motexafin gadolinium Diagnostic / imaging agent

Indications